天天综合色天天综合色hd,久久96国产精品久久,日韩精品中文字幕在线观看

China Surpasses US in Clinical Trials: Leading Global Biotechnology Innovation in 2024 Market Trend China has surpassed the US in clinical trial numbers in 2024, leading global biotech innovation. Major pharma licensing, rising patents, and booming R&D hubs highlight China’s growing dominance in healthcare research.
Zai Lab Breakthrough at ASCO: DLL3 ADC and TTFields Pancreatic Cancer Advances ASCO Discover how biotech leader Zai Lab is making waves at ASCO with groundbreaking DLL3 ADC clinical data and innovative TTFields therapy expanding into pancreatic cancer, driving strong growth and strategic transformation.
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Filing After Trial Misses Survival Goal Biotech Merck and Daiichi Sankyo have withdrawn their FDA application for patritumab deruxtecan after a Phase III trial failed to show significant overall survival benefits in EGFR-mutated NSCLC patients, citing regulatory discussions.
Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding Cuts FDA U.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.
Biogen and City Therapeutics Forge $1B RNAi Partnership Biogen Biogen has partnered with RNAi specialist City Therapeutics in a deal worth up to $1 billion to develop next-generation CNS drugs. The collaboration includes milestone payments, equity investment, and clinical development leadership.
Psychedelic Trial Shows 94% Remission Rate Gilgamesh Pharmaceutical Gilgamesh Pharmaceuticals’ GM-2505 achieved a 94% remission rate in a Phase 2a trial for major depressive disorder. The short-acting psychedelic showed significant, sustained improvements and favorable safety in 40 patients.
FDA Halts Rocket’s Gene Therapy Trial After Fatality FDA Rocket Pharmaceuticals faces an FDA clinical hold on its gene therapy trial for Danon disease following a patient death. The company is reassessing its approach and extending its financial runway into 2027.
Biotech Cuts Jobs Despite $350M Funding Biotech Eikon Therapeutics raised $350M in 2025 to advance its drug pipeline, including Chinese-licensed assets, but recently announced a 15% layoff due to reduced U.S. research funding.
PacBio Expands Long-Read Sequencing Presence in China Amid Illumina Ban PacBio PacBio strengthens its presence in China by expanding distribution of its hi-fi long-read sequencers with Haorui Gene, filling the gap left by Illumina’s import ban amid ongoing US-China trade tensions.
Samsung Biologics to Spin Off Biosimilars Unit Samsung Biologics Samsung Biologics plans to spin off its biosimilars subsidiary, Samsung Bioepis, by October 2025 to address conflict-of-interest concerns and enhance investor value, while continuing strong growth in its CDMO business.

< Pre 123 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a